At close: December 20 at 4:00:01 PM EST
After hours: December 20 at 7:55:41 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
128,456.0000
131,650.0000
118,955.0000
86,429.0000
51,508.0000
Operating Income
-128,456.0000
-131,650.0000
-118,955.0000
-86,429.0000
-51,508.0000
Net Non Operating Interest Income Expense
17,879.0000
14,107.0000
5,588.0000
370.0000
313.0000
Other Income Expense
-32.0000
42.0000
-470.0000
-16.0000
-40,166.0000
Pretax Income
-110,609.0000
-117,501.0000
-113,837.0000
-86,075.0000
-91,361.0000
Net Income Common Stockholders
-110,609.0000
-117,501.0000
-113,837.0000
-86,075.0000
-91,361.0000
Diluted NI Available to Com Stockholders
-110,609.0000
-117,501.0000
-113,837.0000
-86,075.0000
-91,361.0000
Basic EPS
-1.83
-2.40
-2.61
-2.62
-5.44
Diluted EPS
-1.83
-2.40
-2.61
-2.62
-5.44
Basic Average Shares
61,731.2860
49,014.3000
43,631.7220
32,856.8830
16,806.2620
Diluted Average Shares
61,731.2860
49,014.3000
43,631.7220
32,856.8830
16,806.2620
Total Operating Income as Reported
-128,456.0000
-131,650.0000
-118,955.0000
-86,429.0000
-51,508.0000
Total Expenses
128,456.0000
131,650.0000
118,955.0000
86,429.0000
51,508.0000
Net Income from Continuing & Discontinued Operation
-110,609.0000
-117,501.0000
-113,837.0000
-86,075.0000
-91,361.0000
Normalized Income
-110,609.0000
-117,501.0000
-113,837.0000
-86,075.0000
-51,198.0000
Interest Income
17,879.0000
14,107.0000
5,588.0000
370.0000
313.0000
Net Interest Income
17,879.0000
14,107.0000
5,588.0000
370.0000
313.0000
EBIT
-128,456.0000
-131,650.0000
-118,955.0000
-86,429.0000
-51,508.0000
EBITDA
-119,341.0000
-125,781.0000
-116,318.0000
-84,673.0000
-50,722.0000
Reconciled Depreciation
9,115.0000
5,869.0000
2,637.0000
1,756.0000
786.0000
Net Income from Continuing Operation Net Minority Interest
-110,609.0000
-117,501.0000
-113,837.0000
-86,075.0000
-91,361.0000
Total Unusual Items Excluding Goodwill
--
--
--
--
-40,163.0000
Total Unusual Items
--
--
--
--
-40,163.0000
Normalized EBITDA
-119,341.0000
-125,781.0000
-116,318.0000
-84,673.0000
-10,559.0000
12/31/2020 - 7/10/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
STOK Stoke Therapeutics, Inc.
11.68
+3.36%
ALXO ALX Oncology Holdings Inc.
1.6200
+9.46%
ALLO Allogene Therapeutics, Inc.
1.8700
+1.63%
FATE Fate Therapeutics, Inc.
1.6800
+1.20%
GBIO Generation Bio Co.
1.1900
+10.19%
IPSC Century Therapeutics, Inc.
1.1000
+4.76%
DTIL Precision BioSciences, Inc.
4.7200
+2.61%
IMUX Immunic, Inc.
1.0000
-3.85%
INZY Inozyme Pharma, Inc.
2.9900
+6.41%
TCRX TScan Therapeutics, Inc.
2.9700
+1.37%